Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24216249,apparent pA2,"The potency of flumazenil, estimated by apparent pA2 values (95% CI), was 7.30 (7.12, 7.49), 7.17 (7.03, 7.31), 6.91 (6.72, 7.10) and 6.80 (6.67, 6.92) at 15, 30, 60 and 120min after flumazenil administration, respectively.",Quantitative pharmacological analyses of the interaction between flumazenil and midazolam in monkeys discriminating midazolam: Determination of the functional half life of flumazenil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216249/),,7.30,2403,DB01205,Flumazenil
,24216249,apparent pA2,"The potency of flumazenil, estimated by apparent pA2 values (95% CI), was 7.30 (7.12, 7.49), 7.17 (7.03, 7.31), 6.91 (6.72, 7.10) and 6.80 (6.67, 6.92) at 15, 30, 60 and 120min after flumazenil administration, respectively.",Quantitative pharmacological analyses of the interaction between flumazenil and midazolam in monkeys discriminating midazolam: Determination of the functional half life of flumazenil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216249/),,7.17,2404,DB01205,Flumazenil
,24216249,apparent pA2,"The potency of flumazenil, estimated by apparent pA2 values (95% CI), was 7.30 (7.12, 7.49), 7.17 (7.03, 7.31), 6.91 (6.72, 7.10) and 6.80 (6.67, 6.92) at 15, 30, 60 and 120min after flumazenil administration, respectively.",Quantitative pharmacological analyses of the interaction between flumazenil and midazolam in monkeys discriminating midazolam: Determination of the functional half life of flumazenil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216249/),,6.91,2405,DB01205,Flumazenil
,24216249,apparent pA2,"The potency of flumazenil, estimated by apparent pA2 values (95% CI), was 7.30 (7.12, 7.49), 7.17 (7.03, 7.31), 6.91 (6.72, 7.10) and 6.80 (6.67, 6.92) at 15, 30, 60 and 120min after flumazenil administration, respectively.",Quantitative pharmacological analyses of the interaction between flumazenil and midazolam in monkeys discriminating midazolam: Determination of the functional half life of flumazenil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216249/),,6.80,2406,DB01205,Flumazenil
,24216249,functional half life,"The functional half life of flumazenil, derived from potency estimates, was 57±13min.",Quantitative pharmacological analyses of the interaction between flumazenil and midazolam in monkeys discriminating midazolam: Determination of the functional half life of flumazenil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216249/),min,57,2407,DB01205,Flumazenil
,2505960,half-life (t1/2),The mean half-life (t1/2) was 0.8 versus 1.4 hours (p = 0.003) and total plasma clearance was 1201 versus 705 ml per minute (p = 0.009) for control subjects versus patients with cirrhosis.,Flumazenil disposition and elimination in cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505960/),h,0.8,3327,DB01205,Flumazenil
,2505960,half-life (t1/2),The mean half-life (t1/2) was 0.8 versus 1.4 hours (p = 0.003) and total plasma clearance was 1201 versus 705 ml per minute (p = 0.009) for control subjects versus patients with cirrhosis.,Flumazenil disposition and elimination in cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505960/),h,1.4,3328,DB01205,Flumazenil
,2505960,total plasma clearance,The mean half-life (t1/2) was 0.8 versus 1.4 hours (p = 0.003) and total plasma clearance was 1201 versus 705 ml per minute (p = 0.009) for control subjects versus patients with cirrhosis.,Flumazenil disposition and elimination in cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505960/),[ml] / [min],1201,3329,DB01205,Flumazenil
,2505960,total plasma clearance,The mean half-life (t1/2) was 0.8 versus 1.4 hours (p = 0.003) and total plasma clearance was 1201 versus 705 ml per minute (p = 0.009) for control subjects versus patients with cirrhosis.,Flumazenil disposition and elimination in cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505960/),[ml] / [min],705,3330,DB01205,Flumazenil
,2505960,Bioavailability,Bioavailability increased from the normal 28% to 65% (p = 0.001) in patients with hepatic dysfunction.,Flumazenil disposition and elimination in cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505960/),%,28,3331,DB01205,Flumazenil
,2505960,Bioavailability,Bioavailability increased from the normal 28% to 65% (p = 0.001) in patients with hepatic dysfunction.,Flumazenil disposition and elimination in cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505960/),%,65,3332,DB01205,Flumazenil
,3094572,apparent volume of distribution Vss,Ro 15-1788 was rapidly and extensively distributed in the body with an apparent volume of distribution Vss of 1.06 l kg-1.,Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094572/),[l] / [kg],1.06,17951,DB01205,Flumazenil
,3094572,plasma clearance,Elimination occurred rapidly by hepatic metabolism and the high plasma clearance of 1.14 l min-1 resulted in a short elimination half-life of less than 1 h.,Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094572/),[l] / [min],1.14,17952,DB01205,Flumazenil
less,3094572,elimination half-life,Elimination occurred rapidly by hepatic metabolism and the high plasma clearance of 1.14 l min-1 resulted in a short elimination half-life of less than 1 h.,Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094572/),h,1,17953,DB01205,Flumazenil
,3098270,steady state blood levels,Subsequently to an oral loading dose (0.54 g ethanol kg-1) ethanol was infused for 4 h (0.15 g ethanol kg-1 h-1) and steady state blood levels between 0.9 to 1.2 g l-1 were reached within 2 h.,Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098270/),[g] / [l],0.9 to 1.2,27696,DB01205,Flumazenil
,3098270,t1/2,There was no pharmacokinetic interaction between both agents since elimination of Ro 15-1788 (t1/2 = 1.2 +/- 0.7 h) and of ethanol (0.17 +/- 0.02 g l-1 h-1) were in good agreement with control values.,Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098270/),h,1.2,27697,DB01205,Flumazenil
,3098270,t1/2,There was no pharmacokinetic interaction between both agents since elimination of Ro 15-1788 (t1/2 = 1.2 +/- 0.7 h) and of ethanol (0.17 +/- 0.02 g l-1 h-1) were in good agreement with control values.,Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098270/),[g] / [h·l],0.17,27698,DB01205,Flumazenil
,7586951,half-life,"For a light sedation level, with a mean midazolam plasma concentration of 160 +/- 64 ng/ml, the mean half-life of the equilibration rate constant of flumazenil reversal is 5.0 +/- 2.5 minutes, and the mean effect site concentration causing 50% of Emax is 13.7 +/- 5.8 ng/ml.",Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586951/),min,5.0,35591,DB01205,Flumazenil
,7586951,effect site concentration causing 50% of Emax,"For a light sedation level, with a mean midazolam plasma concentration of 160 +/- 64 ng/ml, the mean half-life of the equilibration rate constant of flumazenil reversal is 5.0 +/- 2.5 minutes, and the mean effect site concentration causing 50% of Emax is 13.7 +/- 5.8 ng/ml.",Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586951/),[ng] / [ml],13.7,35592,DB01205,Flumazenil
,7586951,plasma concentration,"For a deep level of sedation, with a mean midazolam plasma concentration of 551 +/- 196 ng/ml, the mean half-life of the equilibration rate constant is 3.9 +/- 1.5 minutes, and the mean effect site concentration causing 50% of Emax is 20.6 +/- 6.8 ng/ml.",Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586951/),ng,55,35593,DB01205,Flumazenil
,7586951,half-life,"For a deep level of sedation, with a mean midazolam plasma concentration of 551 +/- 196 ng/ml, the mean half-life of the equilibration rate constant is 3.9 +/- 1.5 minutes, and the mean effect site concentration causing 50% of Emax is 20.6 +/- 6.8 ng/ml.",Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586951/),min,3.9,35594,DB01205,Flumazenil
,7586951,effect site concentration causing 50% of Emax,"For a deep level of sedation, with a mean midazolam plasma concentration of 551 +/- 196 ng/ml, the mean half-life of the equilibration rate constant is 3.9 +/- 1.5 minutes, and the mean effect site concentration causing 50% of Emax is 20.6 +/- 6.8 ng/ml.",Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586951/),[ng] / [ml],20.6,35595,DB01205,Flumazenil
,3919752,elimination half-life,The rapid elimination of the antagonist could be characterized by an elimination half-life between 0.9 to 1.4 h and a total plasma clearance of 727 to 1440 ml/min.,Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919752/),h,0.9 to 1.4,36181,DB01205,Flumazenil
,3919752,total plasma clearance,The rapid elimination of the antagonist could be characterized by an elimination half-life between 0.9 to 1.4 h and a total plasma clearance of 727 to 1440 ml/min.,Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919752/),[ml] / [min],727 to 1440,36182,DB01205,Flumazenil
,19704033,affinity,"3-tert-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d][1,2,4]triazine (MRK-016) is a pyrazolotriazine with an affinity of between 0.8 and 1.5 nM for the benzodiazepine binding site of native rat brain and recombinant human alpha1-, alpha2-, alpha3-, and alpha5-containing GABA(A) receptors.","In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704033/),nM,0.8 and 1.5,41762,DB01205,Flumazenil
,19704033,EC(50),"MRK-016 gave good receptor occupancy after oral dosing in rats, with the dose required to produce 50% occupancy being 0.39 mg/kg and a corresponding rat plasma EC(50) value of 15 ng/ml that was similar to the rhesus monkey plasma EC(50) value of 21 ng/ml obtained using [(11)C]flumazenil positron emission tomography.","In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704033/),[ng] / [ml],15,41763,DB01205,Flumazenil
,19704033,EC(50),"MRK-016 gave good receptor occupancy after oral dosing in rats, with the dose required to produce 50% occupancy being 0.39 mg/kg and a corresponding rat plasma EC(50) value of 15 ng/ml that was similar to the rhesus monkey plasma EC(50) value of 21 ng/ml obtained using [(11)C]flumazenil positron emission tomography.","In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704033/),[ng] / [ml],21,41764,DB01205,Flumazenil
,19704033,half-life,"MRK-016 had a short half-life in rat, dog, and rhesus monkey (0.3-0.5 h) but had a much lower rate of turnover in human compared with rat, dog, or rhesus monkey hepatocytes.","In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704033/),h,0.3-0.5,41765,DB01205,Flumazenil
,19704033,half-life,"Accordingly, in human, MRK-016 had a longer half-life than in preclinical species ( approximately 3.5 h).","In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704033/),h,3.5,41766,DB01205,Flumazenil
,2044333,',Infusion regimens for flumazenil were designed so that 'steady-state' concentrations of 10 and 20 micrograms/L were obtained.,Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],10,49679,DB01205,Flumazenil
,2044333,steady-state' concentrations,Infusion regimens for flumazenil were designed so that 'steady-state' concentrations of 10 and 20 micrograms/L were obtained.,Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],10,49680,DB01205,Flumazenil
,2044333,steady-state' concentrations,Infusion regimens for flumazenil were designed so that 'steady-state' concentrations of 10 and 20 micrograms/L were obtained.,Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],20,49681,DB01205,Flumazenil
,2044333,plasma drug concentrations,"The mean (+/- SD) plasma drug concentrations of midazolam corresponding to half the maximum increase in TNW12-30 (EC50) were 276 +/- 64, 624 +/- 187 and 1086 +/- 379 micrograms/L in sessions A, B and C, respectively.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],276,49682,DB01205,Flumazenil
,2044333,EC50),"The mean (+/- SD) plasma drug concentrations of midazolam corresponding to half the maximum increase in TNW12-30 (EC50) were 276 +/- 64, 624 +/- 187 and 1086 +/- 379 micrograms/L in sessions A, B and C, respectively.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],276,49683,DB01205,Flumazenil
,2044333,EC50),"The mean (+/- SD) plasma drug concentrations of midazolam corresponding to half the maximum increase in TNW12-30 (EC50) were 276 +/- 64, 624 +/- 187 and 1086 +/- 379 micrograms/L in sessions A, B and C, respectively.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],624,49684,DB01205,Flumazenil
,2044333,EC50),"The mean (+/- SD) plasma drug concentrations of midazolam corresponding to half the maximum increase in TNW12-30 (EC50) were 276 +/- 64, 624 +/- 187 and 1086 +/- 379 micrograms/L in sessions A, B and C, respectively.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],1086,49685,DB01205,Flumazenil
,2044333,half-lives,"The half-lives reflecting equilibration between plasma concentration and effect (t1/2ke0), estimated by a nonparametric method, were 2.2 +/- 1.2, 3.3 +/- 3.3 and 2.9 +/- 1.2 min for the 3 different sessions.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),min,2.2,49686,DB01205,Flumazenil
,2044333,half-lives,"The half-lives reflecting equilibration between plasma concentration and effect (t1/2ke0), estimated by a nonparametric method, were 2.2 +/- 1.2, 3.3 +/- 3.3 and 2.9 +/- 1.2 min for the 3 different sessions.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),min,3.3,49687,DB01205,Flumazenil
,2044333,half-lives,"The half-lives reflecting equilibration between plasma concentration and effect (t1/2ke0), estimated by a nonparametric method, were 2.2 +/- 1.2, 3.3 +/- 3.3 and 2.9 +/- 1.2 min for the 3 different sessions.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),min,2.9,49688,DB01205,Flumazenil
,2044333,EC50,"The plasma concentration of flumazenil that doubled the EC50 of midazolam (Cf,2) was 6.5 +/- 1.0 micrograms/L.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],6.5,49689,DB01205,Flumazenil
,16328648,B (max),"Application of this method in control rats resulted in estimates of B (max) and K (D) (14.5 +/- 3.7 ng/ml and 4.68 +/- 1.5 ng/ml, respectively).",Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16328648/),[ng] / [ml],14.5,53704,DB01205,Flumazenil
,16328648,K (D),"Application of this method in control rats resulted in estimates of B (max) and K (D) (14.5 +/- 3.7 ng/ml and 4.68 +/- 1.5 ng/ml, respectively).",Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16328648/),[ng] / [ml],4.68,53705,DB01205,Flumazenil
,19203567,Apparent oral clearance,"Apparent oral clearance was 2,030 +/- 651 and 1,939 +/- 658 ml/min for the midazolam plus flumazenil and midazolam plus placebo groups.",Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203567/),[ml] / [min],"2,030",53874,DB01205,Flumazenil
,19203567,Apparent oral clearance,"Apparent oral clearance was 2,030 +/- 651 and 1,939 +/- 658 ml/min for the midazolam plus flumazenil and midazolam plus placebo groups.",Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203567/),[ml] / [min],"1,939",53875,DB01205,Flumazenil
,3132551,elimination half-life,"The model was tested with flumazenil (Ro 15-1788), a short-acting benzodiazepine antagonist with an elimination half-life of 1 h.",Experimental model for the investigation of kinetic and/or dynamic interactions between drugs and ethanol in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3132551/),h,1,58606,DB01205,Flumazenil
,1657612,T1/2 beta,"The measured pharmacokinetics of [11C]-flumazenil (T1/2 beta = 45.1 +/- 12.3 min, T1/2 alpha = 1.5 +/- 1.5 min; K = 0.14 +/- 0.14 min-1; Vd area = 44.0 +/- 17.0 l; Clp = 40.0 +/- 8.5 l/h) exhibited a very rapid distribution phase followed by fast elimination, with a large volume of distribution; these results were confirmed by HPLC determinations and agree with previously published data on unlabelled flumazenil.",Plasma pharmacokinetics and metabolism of the benzodiazepine antagonist [11C] Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657612/),min,45.1,74172,DB01205,Flumazenil
,1657612,T1/2 alpha,"The measured pharmacokinetics of [11C]-flumazenil (T1/2 beta = 45.1 +/- 12.3 min, T1/2 alpha = 1.5 +/- 1.5 min; K = 0.14 +/- 0.14 min-1; Vd area = 44.0 +/- 17.0 l; Clp = 40.0 +/- 8.5 l/h) exhibited a very rapid distribution phase followed by fast elimination, with a large volume of distribution; these results were confirmed by HPLC determinations and agree with previously published data on unlabelled flumazenil.",Plasma pharmacokinetics and metabolism of the benzodiazepine antagonist [11C] Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657612/),min,1.5,74173,DB01205,Flumazenil
,1657612,K,"The measured pharmacokinetics of [11C]-flumazenil (T1/2 beta = 45.1 +/- 12.3 min, T1/2 alpha = 1.5 +/- 1.5 min; K = 0.14 +/- 0.14 min-1; Vd area = 44.0 +/- 17.0 l; Clp = 40.0 +/- 8.5 l/h) exhibited a very rapid distribution phase followed by fast elimination, with a large volume of distribution; these results were confirmed by HPLC determinations and agree with previously published data on unlabelled flumazenil.",Plasma pharmacokinetics and metabolism of the benzodiazepine antagonist [11C] Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657612/),1/[min],0.14,74174,DB01205,Flumazenil
,1657612,Vd area,"The measured pharmacokinetics of [11C]-flumazenil (T1/2 beta = 45.1 +/- 12.3 min, T1/2 alpha = 1.5 +/- 1.5 min; K = 0.14 +/- 0.14 min-1; Vd area = 44.0 +/- 17.0 l; Clp = 40.0 +/- 8.5 l/h) exhibited a very rapid distribution phase followed by fast elimination, with a large volume of distribution; these results were confirmed by HPLC determinations and agree with previously published data on unlabelled flumazenil.",Plasma pharmacokinetics and metabolism of the benzodiazepine antagonist [11C] Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657612/),l,44.0,74175,DB01205,Flumazenil
,1657612,Clp,"The measured pharmacokinetics of [11C]-flumazenil (T1/2 beta = 45.1 +/- 12.3 min, T1/2 alpha = 1.5 +/- 1.5 min; K = 0.14 +/- 0.14 min-1; Vd area = 44.0 +/- 17.0 l; Clp = 40.0 +/- 8.5 l/h) exhibited a very rapid distribution phase followed by fast elimination, with a large volume of distribution; these results were confirmed by HPLC determinations and agree with previously published data on unlabelled flumazenil.",Plasma pharmacokinetics and metabolism of the benzodiazepine antagonist [11C] Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657612/),[l] / [h],40.0,74176,DB01205,Flumazenil
,1657612,kf,"Pharmacokinetics of [11C] Ro 15-3890 acid metabolite show that high drug concentrations in the blood are promptly achieved (kf = 0.13 +/- 0.004 min-1), with a very rapid elimination half-life (T1/2m = 4.47 +/- 1.31 min) comparable to that of [11C]-flumazenil.",Plasma pharmacokinetics and metabolism of the benzodiazepine antagonist [11C] Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657612/),1/[min],0.13,74177,DB01205,Flumazenil
,1657612,elimination half-life (T1/2m,"Pharmacokinetics of [11C] Ro 15-3890 acid metabolite show that high drug concentrations in the blood are promptly achieved (kf = 0.13 +/- 0.004 min-1), with a very rapid elimination half-life (T1/2m = 4.47 +/- 1.31 min) comparable to that of [11C]-flumazenil.",Plasma pharmacokinetics and metabolism of the benzodiazepine antagonist [11C] Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657612/),min,4.47,74178,DB01205,Flumazenil
,6419985,elimination half-life,Application of the methods to pharmacokinetic studies in the rat found the elimination half-life of Ro 15-1788 from rat brain to be 16 min.,"Pharmacokinetic studies on Ro 15-1788, a benzodiazepine receptor ligand, in the brain of the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6419985/),min,16,77418,DB01205,Flumazenil
,1309878,Emax,"An agonist-antagonist interaction model was used to quantify the interaction, yielding the pharmacodynamic parameters of midazolam [(mean +/- S.E.): Emax = 80 +/- 5 microV/sec, EC50 = 35 +/- 3 ng/ml and N = 1.1 +/- 0.2] and flumazenil: EC50 = 24 +/- 2 ng/ml and N = 1.6 +/- 0.1.",In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1309878/),[μv] / [s],80,87944,DB01205,Flumazenil
,1309878,EC50,"An agonist-antagonist interaction model was used to quantify the interaction, yielding the pharmacodynamic parameters of midazolam [(mean +/- S.E.): Emax = 80 +/- 5 microV/sec, EC50 = 35 +/- 3 ng/ml and N = 1.1 +/- 0.2] and flumazenil: EC50 = 24 +/- 2 ng/ml and N = 1.6 +/- 0.1.",In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1309878/),[ng] / [ml],35,87945,DB01205,Flumazenil
,1309878,N,"An agonist-antagonist interaction model was used to quantify the interaction, yielding the pharmacodynamic parameters of midazolam [(mean +/- S.E.): Emax = 80 +/- 5 microV/sec, EC50 = 35 +/- 3 ng/ml and N = 1.1 +/- 0.2] and flumazenil: EC50 = 24 +/- 2 ng/ml and N = 1.6 +/- 0.1.",In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1309878/),,1.1,87946,DB01205,Flumazenil
,1309878,EC50,"An agonist-antagonist interaction model was used to quantify the interaction, yielding the pharmacodynamic parameters of midazolam [(mean +/- S.E.): Emax = 80 +/- 5 microV/sec, EC50 = 35 +/- 3 ng/ml and N = 1.1 +/- 0.2] and flumazenil: EC50 = 24 +/- 2 ng/ml and N = 1.6 +/- 0.1.",In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1309878/),[ng] / [ml],24,87947,DB01205,Flumazenil
,1309878,N,"An agonist-antagonist interaction model was used to quantify the interaction, yielding the pharmacodynamic parameters of midazolam [(mean +/- S.E.): Emax = 80 +/- 5 microV/sec, EC50 = 35 +/- 3 ng/ml and N = 1.1 +/- 0.2] and flumazenil: EC50 = 24 +/- 2 ng/ml and N = 1.6 +/- 0.1.",In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1309878/),,1.6,87948,DB01205,Flumazenil
,8113798,maximal binding,"Its rapid cerebral kinetics is consistent with a hypnotic profile (maximal binding after 23 min, elimination half-life of 202 min).",In vivo high intrinsic efficacy of triazolam: a positron emission tomography study in nonhuman primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8113798/),min,23,88000,DB01205,Flumazenil
,8113798,elimination half-life,"Its rapid cerebral kinetics is consistent with a hypnotic profile (maximal binding after 23 min, elimination half-life of 202 min).",In vivo high intrinsic efficacy of triazolam: a positron emission tomography study in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8113798/),min,202,88001,DB01205,Flumazenil
,8113798,ID50,Triazolam is very potent in displacing [11C]flumazenil (ID50 = 28 +/- 6 micrograms/kg).,In vivo high intrinsic efficacy of triazolam: a positron emission tomography study in nonhuman primates. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8113798/),[μg] / [kg],28,88002,DB01205,Flumazenil
,2109476,biological half-life,"Due to its biological half-life of 150-180 min and interindividual differences in drug susceptibility, prolonged recovery periods have been observed that can safely and reliably be antagonised by flumazenil, if necessary.",Anaesthesia techniques for midazolam and flumazenil--an overview. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109476/),min,150-180,88516,DB01205,Flumazenil
,15578749,bioavailability,"In both species L-838417 was well absorbed following i.p. administration and whilst in rats p.o. bioavailability was good (41%), in mice it was negligible (<1%), precluding this as a route of administration for mouse behavioural studies.",Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578749/),%,41,95370,DB01205,Flumazenil
<,15578749,bioavailability,"In both species L-838417 was well absorbed following i.p. administration and whilst in rats p.o. bioavailability was good (41%), in mice it was negligible (<1%), precluding this as a route of administration for mouse behavioural studies.",Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578749/),%,1,95371,DB01205,Flumazenil
,15578749,volume of distribution,"Despite having a similar volume of distribution (ca 1.4 l/kg) in rats and mice, L-838417 was cleared at twice liver blood flow in mice (161 ml/min/kg) and moderately cleared in rats (24 ml/min/kg), potentially explaining the poor oral bioavailability in mice.",Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578749/),[l] / [kg],1.4,95372,DB01205,Flumazenil
,12496752,AUC ratio,"The AUC ratio (flumazenil plus midazolam/midazolam) was 0.99, with a 90% confidence interval of 0.98 to 1.00.",Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496752/),,0.,96363,DB01205,Flumazenil
,6409127,sensitivity,The sensitivity limit was about 10 ng/ml plasma using a 1-ml specimen.,Determination of the benzodiazepine antagonist Ro 15-1788 in plasma by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6409127/),[ng] / [ml],10,99121,DB01205,Flumazenil
,2057540,terminal half-life,"Following intravenous administration flumazenil was rapidly eliminated with an extremely short terminal half-life (mean +/- SE, n = 8) of 8.3 +/- 0.3 min due to a large total blood clearance of 147 +/- 7 ml/kg/min combined with a relatively small volume of distribution at steady-state of 1.33 +/- 0.07 l/kg.",Stability and pharmacokinetics of flumazenil in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057540/),min,8.3,112638,DB01205,Flumazenil
,2057540,total blood clearance,"Following intravenous administration flumazenil was rapidly eliminated with an extremely short terminal half-life (mean +/- SE, n = 8) of 8.3 +/- 0.3 min due to a large total blood clearance of 147 +/- 7 ml/kg/min combined with a relatively small volume of distribution at steady-state of 1.33 +/- 0.07 l/kg.",Stability and pharmacokinetics of flumazenil in the rat. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057540/),[ml] / [kg·min],147,112639,DB01205,Flumazenil
,2057540,volume of distribution at steady-state,"Following intravenous administration flumazenil was rapidly eliminated with an extremely short terminal half-life (mean +/- SE, n = 8) of 8.3 +/- 0.3 min due to a large total blood clearance of 147 +/- 7 ml/kg/min combined with a relatively small volume of distribution at steady-state of 1.33 +/- 0.07 l/kg.",Stability and pharmacokinetics of flumazenil in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057540/),[l] / [kg],1.33,112640,DB01205,Flumazenil
,2057540,bioavailability,"After oral administration flumazenil was rapidly absorbed; however, the bioavailability was low (28 +/- 4%) and variable.",Stability and pharmacokinetics of flumazenil in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057540/),%,28,112641,DB01205,Flumazenil
,2057540,half-life,"Flumazenil was found to be unstable in rat blood in vitro and disappeared with a half-life (mean +/- SE, n = 5) of 8.3 +/- 1 min and 31 +/- 4 min at body and room temperature, respectively.",Stability and pharmacokinetics of flumazenil in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057540/),min,8.3,112642,DB01205,Flumazenil
,2057540,half-life,"Flumazenil was found to be unstable in rat blood in vitro and disappeared with a half-life (mean +/- SE, n = 5) of 8.3 +/- 1 min and 31 +/- 4 min at body and room temperature, respectively.",Stability and pharmacokinetics of flumazenil in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057540/),min,31,112643,DB01205,Flumazenil
,2511137,plasma clearance,"In controls, Ro 15-1788 had a high plasma clearance [16.3 +/- 2.6 ml per min per kg (mean +/- S.D.)], a short half-life (45.7 +/- 8.5 min), a large volume of distribution (0.62 +/- 0.09 liter per kg) and a low plasma protein binding (45 +/- 6%).",Pharmacokinetics of benzodiazepine antagonist Ro 15-1788 in cirrhotic patients with moderate or severe liver dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511137/),[ml] / [kg·min],16.3,113567,DB01205,Flumazenil
,2511137,half-life,"In controls, Ro 15-1788 had a high plasma clearance [16.3 +/- 2.6 ml per min per kg (mean +/- S.D.)], a short half-life (45.7 +/- 8.5 min), a large volume of distribution (0.62 +/- 0.09 liter per kg) and a low plasma protein binding (45 +/- 6%).",Pharmacokinetics of benzodiazepine antagonist Ro 15-1788 in cirrhotic patients with moderate or severe liver dysfunction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511137/),min,45.7,113568,DB01205,Flumazenil
,2511137,volume of distribution,"In controls, Ro 15-1788 had a high plasma clearance [16.3 +/- 2.6 ml per min per kg (mean +/- S.D.)], a short half-life (45.7 +/- 8.5 min), a large volume of distribution (0.62 +/- 0.09 liter per kg) and a low plasma protein binding (45 +/- 6%).",Pharmacokinetics of benzodiazepine antagonist Ro 15-1788 in cirrhotic patients with moderate or severe liver dysfunction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511137/),[l] / [kg],0.62,113569,DB01205,Flumazenil
,2511137,plasma protein binding,"In controls, Ro 15-1788 had a high plasma clearance [16.3 +/- 2.6 ml per min per kg (mean +/- S.D.)], a short half-life (45.7 +/- 8.5 min), a large volume of distribution (0.62 +/- 0.09 liter per kg) and a low plasma protein binding (45 +/- 6%).",Pharmacokinetics of benzodiazepine antagonist Ro 15-1788 in cirrhotic patients with moderate or severe liver dysfunction. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511137/),%,45,113570,DB01205,Flumazenil
,8471371,elimination half-life,"Midazolam data were consistent with a three-compartment model with a mean (SD) elimination half-life of 107 (30) min, total body clearance of 15.4 (3.2) ml min-1 kg-1 and apparent volume of distribution at steady state of 1.9 (0.6) litre kg-1.",Pharmacokinetics of flumazenil and midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),min,107,118266,DB01205,Flumazenil
,8471371,total body clearance,"Midazolam data were consistent with a three-compartment model with a mean (SD) elimination half-life of 107 (30) min, total body clearance of 15.4 (3.2) ml min-1 kg-1 and apparent volume of distribution at steady state of 1.9 (0.6) litre kg-1.",Pharmacokinetics of flumazenil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),[ml] / [kg·min],15.4,118267,DB01205,Flumazenil
,8471371,apparent volume of distribution at steady state,"Midazolam data were consistent with a three-compartment model with a mean (SD) elimination half-life of 107 (30) min, total body clearance of 15.4 (3.2) ml min-1 kg-1 and apparent volume of distribution at steady state of 1.9 (0.6) litre kg-1.",Pharmacokinetics of flumazenil and midazolam. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),[l] / [kg],1.9,118268,DB01205,Flumazenil
,8471371,terminal elimination half-life,"Flumazenil data were best interpreted by a monoexponential function, with a mean terminal elimination half-life of 35.3 (13.8) min, a total plasma clearance of 20.6 (6.9) ml min-1 kg-1 and apparent volume of distribution at steady state of 1.0 (0.2) litre kg-1.",Pharmacokinetics of flumazenil and midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),min,35.3,118269,DB01205,Flumazenil
,8471371,total plasma clearance,"Flumazenil data were best interpreted by a monoexponential function, with a mean terminal elimination half-life of 35.3 (13.8) min, a total plasma clearance of 20.6 (6.9) ml min-1 kg-1 and apparent volume of distribution at steady state of 1.0 (0.2) litre kg-1.",Pharmacokinetics of flumazenil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),[ml] / [kg·min],20.6,118270,DB01205,Flumazenil
,8471371,apparent volume of distribution at steady state,"Flumazenil data were best interpreted by a monoexponential function, with a mean terminal elimination half-life of 35.3 (13.8) min, a total plasma clearance of 20.6 (6.9) ml min-1 kg-1 and apparent volume of distribution at steady state of 1.0 (0.2) litre kg-1.",Pharmacokinetics of flumazenil and midazolam. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),[l] / [kg],1.0,118271,DB01205,Flumazenil
,8471371,plasma concentrations,"At the time of self identification, 4.5 (1.4) min after flumazenil administration, the mean plasma concentrations of midazolam and flumazenil were 163.1 (43.7) and 29.9 (16.1) ng ml-1, respectively.",Pharmacokinetics of flumazenil and midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),[ng] / [ml],163.1,118272,DB01205,Flumazenil
,8471371,plasma concentrations,"At the time of self identification, 4.5 (1.4) min after flumazenil administration, the mean plasma concentrations of midazolam and flumazenil were 163.1 (43.7) and 29.9 (16.1) ng ml-1, respectively.",Pharmacokinetics of flumazenil and midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),[ng] / [ml],29.9,118273,DB01205,Flumazenil
,10674504,Cmax,"Mean Cmax was 67.8 ng x mL(-1) (SD 41.9), with Tmax at two minutes.",Plasma concentration of flumazenil following intranasal administration in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674504/),[ng] / [ml],67.8,120960,DB01205,Flumazenil
,10674504,Tmax,"Mean Cmax was 67.8 ng x mL(-1) (SD 41.9), with Tmax at two minutes.",Plasma concentration of flumazenil following intranasal administration in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674504/),min,two,120961,DB01205,Flumazenil
,10674504,half-life,The calculated half-life was 122 min (SD 99).,Plasma concentration of flumazenil following intranasal administration in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674504/),min,122,120962,DB01205,Flumazenil
,15848211,Recoveries,"Recoveries ranged from 89.7 to 96.6% and from 80.2 to 85.3% for FL and nor-FL, respectively.",Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: application to clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848211/),%,89.7 to 96.6,124818,DB01205,Flumazenil
,15848211,Recoveries,"Recoveries ranged from 89.7 to 96.6% and from 80.2 to 85.3% for FL and nor-FL, respectively.",Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: application to clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848211/),%,80.2 to 85.3,124819,DB01205,Flumazenil
,8521677,absolute bio-availability,Zolpidem is approximately 92% bound to plasma proteins; absolute bio-availability of zolpidem is about 70%.,Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),%,70,127592,DB01205,Flumazenil
,8521677,peak plasma concentration,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[μg] / [l],192 to 324,127593,DB01205,Flumazenil
,8521677,terminal elimination half-line,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),h,1.5 to 3.2,127594,DB01205,Flumazenil
,8521677,total clearance,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[ml] / [kg·min],0.24 to 0.27,127595,DB01205,Flumazenil
,20407249,elimination half-life,"Remifentanil, due to its pharmacokinetic profile (elimination half-life: 9 min), is advantageous for ambulatory patients, though it is not known whether the high cost compensates the benefits.",Pharmacology of sedation agents and reversal agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20407249/),min,9,139670,DB01205,Flumazenil
,1336860,half-life,"Washout of cortical radioactivity was regionally variable but relatively slow, with a half-life of approximately 4 hours after the time of peak radioactivity.",Dynamic SPECT imaging after injection of the benzodiazepine receptor ligand [123I]iomazenil in healthy human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336860/),h,4,144288,DB01205,Flumazenil
,3127102,bioavailability,"Following oral administration flumazenil is rapidly absorbed (peak concentrations are achieved after 20 to 90 minutes), but bioavailability is low (16%) due to significant presystemic elimination.",Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127102/),%,16,149211,DB01205,Flumazenil
,3127102,half-life,This can be characterised either by the short half-life (0.7 to 1.3 hours) or better by the high plasma or blood clearance of 520 to 1300 ml/min (31 to 78 L/h).,Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127102/),h,0.7 to 1.3,149212,DB01205,Flumazenil
,3127102,plasma,This can be characterised either by the short half-life (0.7 to 1.3 hours) or better by the high plasma or blood clearance of 520 to 1300 ml/min (31 to 78 L/h).,Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127102/),[ml] / [min],520 to 1300,149213,DB01205,Flumazenil
,3127102,blood clearance,This can be characterised either by the short half-life (0.7 to 1.3 hours) or better by the high plasma or blood clearance of 520 to 1300 ml/min (31 to 78 L/h).,Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127102/),[ml] / [min],520 to 1300,149214,DB01205,Flumazenil
,3127102,blood clearance,This can be characterised either by the short half-life (0.7 to 1.3 hours) or better by the high plasma or blood clearance of 520 to 1300 ml/min (31 to 78 L/h).,Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127102/),[l] / [h],31 to 78,149215,DB01205,Flumazenil
,3127102,plasma protein binding,The low plasma protein binding of flumazenil (about 40%) will not limit its wide distribution (apparent distribution volume 0.6 to 1.6 L/kg) or its partly flow-dependent hepatic elimination.,Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127102/),%,40,149216,DB01205,Flumazenil
,3127102,apparent distribution volume,The low plasma protein binding of flumazenil (about 40%) will not limit its wide distribution (apparent distribution volume 0.6 to 1.6 L/kg) or its partly flow-dependent hepatic elimination.,Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127102/),[l] / [kg],0.6 to 1.6,149217,DB01205,Flumazenil
,3140563,elimination half-life,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),h,3.9,149435,DB01205,Flumazenil
,3140563,elimination half-life,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),h,1.2,149436,DB01205,Flumazenil
,3140563,apparent volume of distribution,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),l,107,149437,DB01205,Flumazenil
,3140563,apparent volume of distribution,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),l,31,149438,DB01205,Flumazenil
,3140563,total body clearance,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),[l] / [h],20,149439,DB01205,Flumazenil
,3140563,total body clearance,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),[l] / [h],18,149440,DB01205,Flumazenil
,2513818,t1/2,"Due to its rapid hepatic elimination (t1/2 approximately 0.8-1.2 h; systemic clearance approximately 700-1,200 ml/min) with a single dose of 0.2 to 1 mg, the desired level of consciousness is attained for only about 2 hours.",[Clinical pharmacology and therapeutic uses of the specific benzodiazepine antagonist flumazenil]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2513818/),h,0.8-1.2,157254,DB01205,Flumazenil
,2513818,systemic clearance,"Due to its rapid hepatic elimination (t1/2 approximately 0.8-1.2 h; systemic clearance approximately 700-1,200 ml/min) with a single dose of 0.2 to 1 mg, the desired level of consciousness is attained for only about 2 hours.",[Clinical pharmacology and therapeutic uses of the specific benzodiazepine antagonist flumazenil]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2513818/),[ml] / [min],"700-1,200",157255,DB01205,Flumazenil
,6436030,t1/2,"Hepatic elimination was rapid, as shown by a short t1/2 of 0.9 +/- 0.2 h, and high total plasma and blood clearances of 691 +/- 216 ml/min and 716 +/- 199 ml/min, respectively.",Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436030/),h,0.9,160646,DB01205,Flumazenil
,6436030,total plasma,"Hepatic elimination was rapid, as shown by a short t1/2 of 0.9 +/- 0.2 h, and high total plasma and blood clearances of 691 +/- 216 ml/min and 716 +/- 199 ml/min, respectively.",Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436030/),[ml] / [min],691,160647,DB01205,Flumazenil
,6436030,blood clearances,"Hepatic elimination was rapid, as shown by a short t1/2 of 0.9 +/- 0.2 h, and high total plasma and blood clearances of 691 +/- 216 ml/min and 716 +/- 199 ml/min, respectively.",Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436030/),[ml] / [min],716,160648,DB01205,Flumazenil
,10704271,half-lives for distribution,The half-lives for distribution ( approximately 0.14 h) and elimination ( approximately 5.4 h) are not related to dose.,"Pharmacokinetics of the peripheral benzodiazepine receptor antagonist, PK 11195, in rats. The effect of dose and gender. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704271/),h,0.14,180188,DB01205,Flumazenil
,10704271,elimination,The half-lives for distribution ( approximately 0.14 h) and elimination ( approximately 5.4 h) are not related to dose.,"Pharmacokinetics of the peripheral benzodiazepine receptor antagonist, PK 11195, in rats. The effect of dose and gender. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704271/),h,5.4,180189,DB01205,Flumazenil
,10704271,volume of distribution,The large volume of distribution (9-24 l kg(-1)) indicates an extensive distribution outside plasma.,"Pharmacokinetics of the peripheral benzodiazepine receptor antagonist, PK 11195, in rats. The effect of dose and gender. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704271/),[l] / [kg],9-24,180190,DB01205,Flumazenil
,10704271,Total plasma clearance,Total plasma clearance increases with increasing dose (23-42 ml min(-1)kg(-1)).,"Pharmacokinetics of the peripheral benzodiazepine receptor antagonist, PK 11195, in rats. The effect of dose and gender. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704271/),[ml] / [min],23-42,180191,DB01205,Flumazenil
,10704271,brain/plasma ratio,The brain/plasma ratio ( approximately 3) is not related to dose.,"Pharmacokinetics of the peripheral benzodiazepine receptor antagonist, PK 11195, in rats. The effect of dose and gender. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704271/),,3,180192,DB01205,Flumazenil
,33673881,terminal half-life,"FLU terminal half-life, plasma clearance and volume of distribution were 26.3 min [95%CI: 23.3 to 29.3], 18.74 mL/min/kg [16.47 to 21.00] and 0.63 L/kg [0.55 to 0.71], respectively.",A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (Oryctolagus cuniculus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33673881/),min,26.3,183456,DB01205,Flumazenil
,33673881,plasma clearance,"FLU terminal half-life, plasma clearance and volume of distribution were 26.3 min [95%CI: 23.3 to 29.3], 18.74 mL/min/kg [16.47 to 21.00] and 0.63 L/kg [0.55 to 0.71], respectively.",A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (Oryctolagus cuniculus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33673881/),[ml] / [kg·min],18.74,183457,DB01205,Flumazenil
,33673881,volume of distribution,"FLU terminal half-life, plasma clearance and volume of distribution were 26.3 min [95%CI: 23.3 to 29.3], 18.74 mL/min/kg [16.47 to 21.00] and 0.63 L/kg [0.55 to 0.71], respectively.",A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (Oryctolagus cuniculus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33673881/),[l] / [kg],0.63,183458,DB01205,Flumazenil
,33673881,ReRR,ReRR was 25 times faster in rabbits treated with FLU (23 [8 to 44] s) compared with SAL (576 [130 to 1141] s; 95%CI [425 to 914 s]).,A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (Oryctolagus cuniculus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33673881/),s,23,183459,DB01205,Flumazenil
,33673881,ReRR,ReRR was 25 times faster in rabbits treated with FLU (23 [8 to 44] s) compared with SAL (576 [130 to 1141] s; 95%CI [425 to 914 s]).,A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (Oryctolagus cuniculus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33673881/),s,576,183460,DB01205,Flumazenil
,8157048,volume of distribution (Vss),After 2 mg i.v. the disposition parameters in the two age groups (elderly/young) were very similar: volume of distribution (Vss): 0.88/0.90 l.kg-1; total body clearance (ClPL): 0.86/0.99 l.min-1; terminal elimination half-life (t1/2 beta): 1.02/0.91 h.,Flumazenil kinetics in the elderly. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157048/),[l] / [kg],0.88,184397,DB01205,Flumazenil
,8157048,volume of distribution (Vss),After 2 mg i.v. the disposition parameters in the two age groups (elderly/young) were very similar: volume of distribution (Vss): 0.88/0.90 l.kg-1; total body clearance (ClPL): 0.86/0.99 l.min-1; terminal elimination half-life (t1/2 beta): 1.02/0.91 h.,Flumazenil kinetics in the elderly. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157048/),[l] / [kg],0.90,184398,DB01205,Flumazenil
,8157048,total body clearance (ClPL),After 2 mg i.v. the disposition parameters in the two age groups (elderly/young) were very similar: volume of distribution (Vss): 0.88/0.90 l.kg-1; total body clearance (ClPL): 0.86/0.99 l.min-1; terminal elimination half-life (t1/2 beta): 1.02/0.91 h.,Flumazenil kinetics in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157048/),[l] / [min],0.86,184399,DB01205,Flumazenil
,8157048,total body clearance (ClPL),After 2 mg i.v. the disposition parameters in the two age groups (elderly/young) were very similar: volume of distribution (Vss): 0.88/0.90 l.kg-1; total body clearance (ClPL): 0.86/0.99 l.min-1; terminal elimination half-life (t1/2 beta): 1.02/0.91 h.,Flumazenil kinetics in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157048/),[l] / [min],0.99,184400,DB01205,Flumazenil
,8157048,terminal elimination half-life (t1/2 beta),After 2 mg i.v. the disposition parameters in the two age groups (elderly/young) were very similar: volume of distribution (Vss): 0.88/0.90 l.kg-1; total body clearance (ClPL): 0.86/0.99 l.min-1; terminal elimination half-life (t1/2 beta): 1.02/0.91 h.,Flumazenil kinetics in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157048/),h,1.02,184401,DB01205,Flumazenil
,8157048,Cmax,After the 30 mg oral dose the mean Cmax of 87.6 ng.,Flumazenil kinetics in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157048/),ng,87.6,184402,DB01205,Flumazenil
,8157048,absolute bioavailability,"In 26% (elderly) and 23% (young), the absolute bioavailability of flumazenil was very similar.",Flumazenil kinetics in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157048/),%,23,184403,DB01205,Flumazenil
,2114299,Active,"After acute dosing, clobazam significantly reduced all parameters of kindled seizures (seizure severity, seizure duration, duration of amygdalar afterdischarges) at doses of 7.5 or 10 mg/kg i.p. 'Active' plasma concentrations of clobazam ranged between 300-800 ng/ml.",Development of tolerance to clobazam in fully kindled rats: effects of intermittent flumazenil administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2114299/),[ng] / [ml],300-800,193769,DB01205,Flumazenil
,2114299,elimination half-life,The elimination half-life of clobazam in plasma was about 1 h.,Development of tolerance to clobazam in fully kindled rats: effects of intermittent flumazenil administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2114299/),h,1,193770,DB01205,Flumazenil
,11132509,Bioavailability,"Bioavailability of SM flumazenil was 101 +/- 14%, based upon measuring the area under the serum concentration-time curves over 1.5 h (AUC 0-1.5 h, SM vs. i.v. drug).",Comparative pharmacokinetics of submucosal vs. intravenous flumazenil (Romazicon) in an animal model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11132509/),%,101,194019,DB01205,Flumazenil
,27071281,recovery,The applied analitycal method showed excellent recovery (94.65%).,Determination of flumazenil in serum by liquid chromatography-mass spectrometry: Application to kinetics study in acute diazepam overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27071281/),%,94.65,201137,DB01205,Flumazenil
,16236037,CL,"Mean population pharmacokinetic parameters (percent coefficient of variation) were: CL 1530 mL min(-1) (6.6%), V(1) 24.8 x 10(3) mL (3.8%), V(2) 27.3 x 10(3) mL (5.4%), and Q 2510 mL min(-1) (6.5%).",Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236037/),[ml] / [min],1530,201169,DB01205,Flumazenil
,16236037,V(1),"Mean population pharmacokinetic parameters (percent coefficient of variation) were: CL 1530 mL min(-1) (6.6%), V(1) 24.8 x 10(3) mL (3.8%), V(2) 27.3 x 10(3) mL (5.4%), and Q 2510 mL min(-1) (6.5%).",Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236037/),ml,24.8 x 10(3),201170,DB01205,Flumazenil
,16236037,V(2),"Mean population pharmacokinetic parameters (percent coefficient of variation) were: CL 1530 mL min(-1) (6.6%), V(1) 24.8 x 10(3) mL (3.8%), V(2) 27.3 x 10(3) mL (5.4%), and Q 2510 mL min(-1) (6.5%).",Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236037/),ml,27.3 x 10(3),201171,DB01205,Flumazenil
,16236037,Q,"Mean population pharmacokinetic parameters (percent coefficient of variation) were: CL 1530 mL min(-1) (6.6%), V(1) 24.8 x 10(3) mL (3.8%), V(2) 27.3 x 10(3) mL (5.4%), and Q 2510 mL min(-1) (6.5%).",Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236037/),[ml] / [min],2510,201172,DB01205,Flumazenil
,16236037,V(1),"CL was 20% lower in patients with epilepsy, and the influence of weight on V(1) was 0.55% kg(-1).",Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236037/),[%] / [kg],0.55,201173,DB01205,Flumazenil
,16236037,AUC,"The optimal sampling strategy was cross-validated (observed AUC = 296 MBql(-1) min(-1) (95% CI 102-490), predicted AUC = 288 MBql(-1) min(-1) (95% CI 70-506)).",Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236037/),1/[Mbql·min],296,201174,DB01205,Flumazenil
,16236037,AUC,"The optimal sampling strategy was cross-validated (observed AUC = 296 MBql(-1) min(-1) (95% CI 102-490), predicted AUC = 288 MBql(-1) min(-1) (95% CI 70-506)).",Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236037/),1/[Mbql·min],288,201175,DB01205,Flumazenil
,2842128,absorption half-life,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),min,20-90,206677,DB01205,Flumazenil
,2842128,absorption half-life,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),h,0.3,206678,DB01205,Flumazenil
,2842128,bio-availability,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),%,16,206679,DB01205,Flumazenil
,2842128,half-life,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),h,0.7-1.3,206680,DB01205,Flumazenil
,2842128,plasma,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),[ml] / [min],520-1300,206681,DB01205,Flumazenil
,2842128,blood clearance,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),[ml] / [min],520-1300,206682,DB01205,Flumazenil
,2842128,plasma protein binding,The low plasma protein binding of flumazenil (about 40%) will not limit its wide distribution (apparent distribution volume 0.6-1 kg) or its partly flow-dependent hepatic elimination.,Drug interactions and clinical pharmacokinetics of flumazenil. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),%,40,206683,DB01205,Flumazenil
,2842128,apparent distribution volume,The low plasma protein binding of flumazenil (about 40%) will not limit its wide distribution (apparent distribution volume 0.6-1 kg) or its partly flow-dependent hepatic elimination.,Drug interactions and clinical pharmacokinetics of flumazenil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),kg,0.6-1,206684,DB01205,Flumazenil
,23404347,half-life,Their pharmacokinetics approach those of the ideal hypnotic with rapid onset within 30 min and short half-life (1-7 h).,The clinical and forensic toxicology of Z-drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23404347/),h,1-7,214122,DB01205,Flumazenil
,7955817,half-life,"Flumazenil exhibited a rapid onset (the half-life of equilibration between drug concentration in the blood and drug effect was 3.3 minutes) and short duration of action (the flumazenil plasma concentration causing half-maximal effect was 7.4 ng/ml, which was reached about 1 hour after dosing).",The pharmacokinetic-pharmacodynamic (Digit Symbol Substitution Test) relationship of flumazenil in a midazolam steady-state model in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955817/),min,3.3,218041,DB01205,Flumazenil
,7955817,plasma concentration causing half-maximal effect,"Flumazenil exhibited a rapid onset (the half-life of equilibration between drug concentration in the blood and drug effect was 3.3 minutes) and short duration of action (the flumazenil plasma concentration causing half-maximal effect was 7.4 ng/ml, which was reached about 1 hour after dosing).",The pharmacokinetic-pharmacodynamic (Digit Symbol Substitution Test) relationship of flumazenil in a midazolam steady-state model in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955817/),[ng] / [ml],7.4,218042,DB01205,Flumazenil
,32178858,time to full alertness,The end-of-infusion injection of flumazenil shortened the median time to full alertness to 3.5 min and effectively reversed psychomotor and cardiovascular dysfunction.,Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32178858/),min,3.5,242074,DB01205,Flumazenil
,9517696,peak plasma flumazenil concentration,An average peak plasma flumazenil concentration of 65.9 +/- 43.1 ng/mL was attained within 1 minute after administration.,Endotracheal flumazenil: a new route of administration for benzodiazepine antagonism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517696/),[ng] / [ml],65.9,249038,DB01205,Flumazenil
,1350744,Emax,"Large differences in maximal effect of midazolam (Emax = 73 +/- 2 microVs-1), bretazenil (Emax = 19 +/- 1 microVs-1) and Ro 19-4603 (Emax = -6.5 +/- 0.4 microVs-1) were observed, reflecting their differences in intrinsic efficacy.",Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1350744/),1/[μvs],73,254600,DB01205,Flumazenil
,1350744,Emax,"Large differences in maximal effect of midazolam (Emax = 73 +/- 2 microVs-1), bretazenil (Emax = 19 +/- 1 microVs-1) and Ro 19-4603 (Emax = -6.5 +/- 0.4 microVs-1) were observed, reflecting their differences in intrinsic efficacy.",Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1350744/),1/[μvs],19,254601,DB01205,Flumazenil
,1350744,Emax,"Large differences in maximal effect of midazolam (Emax = 73 +/- 2 microVs-1), bretazenil (Emax = 19 +/- 1 microVs-1) and Ro 19-4603 (Emax = -6.5 +/- 0.4 microVs-1) were observed, reflecting their differences in intrinsic efficacy.",Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1350744/),1/[μvs],-6.5,254602,DB01205,Flumazenil
,19422390,EC(50),"However, rat plasma EC(50) was time-independent, ranging from 42 to 67 ngxmL(-1) over a 24 h time course with the average being 52 ngxmL(-1) (i.e. occupancy decreased as plasma drug concentrations fell).","The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19422390/),[ng] / [ml],42 to 67,266094,DB01205,Flumazenil
,19422390,EC(50),"However, rat plasma EC(50) was time-independent, ranging from 42 to 67 ngxmL(-1) over a 24 h time course with the average being 52 ngxmL(-1) (i.e. occupancy decreased as plasma drug concentrations fell).","The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19422390/),[ng] / [ml],52,266095,DB01205,Flumazenil
,19422390,EC(50),"In rhesus monkeys, the EC(50) for alpha5IA displacing steady-state [(123)I]iomazenil binding was 57 ngxmL(-1).","The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19422390/),[ng] / [ml],57,266096,DB01205,Flumazenil
,19422390,EC(50),"These data also suggest that despite the different assays used (terminal assays of [(3)H]flumazenil in vivo binding in rats and [(123)I]iomazenil gamma-scintigraphy in anaesthetized rhesus monkeys), these techniques produced similar plasma alpha5IA EC(50) values (52 and 57 ngxmL(-1) respectively) and that the plasma-occupancy relationship for alpha5IA translates across these two species.","The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19422390/),[ng] / [ml],52,266097,DB01205,Flumazenil
,19422390,EC(50),"These data also suggest that despite the different assays used (terminal assays of [(3)H]flumazenil in vivo binding in rats and [(123)I]iomazenil gamma-scintigraphy in anaesthetized rhesus monkeys), these techniques produced similar plasma alpha5IA EC(50) values (52 and 57 ngxmL(-1) respectively) and that the plasma-occupancy relationship for alpha5IA translates across these two species.","The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19422390/),[ng] / [ml],57,266098,DB01205,Flumazenil
,2108448,elimination half life,Oxazepam is eliminated with a relatively short elimination half life (ca. 150 min) in both acutely and chronically treated dogs.,The effects of flumazenil-precipitated abstinence on the pharmacokinetics of chronic oxazepam in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2108448/),min,150,266373,DB01205,Flumazenil
,2108448,first pass metabolism,It exhibits only a modest first pass metabolism (ca. 10%) and its bioavailability following oral administration is about 22%.,The effects of flumazenil-precipitated abstinence on the pharmacokinetics of chronic oxazepam in dogs. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2108448/),%,10,266374,DB01205,Flumazenil
,2108448,bioavailability,It exhibits only a modest first pass metabolism (ca. 10%) and its bioavailability following oral administration is about 22%.,The effects of flumazenil-precipitated abstinence on the pharmacokinetics of chronic oxazepam in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2108448/),%,22,266375,DB01205,Flumazenil
,2044332,initial volume of distribution,"The pharmacokinetic parameters were (mean +/- SD): initial volume of distribution, 16 +/- 5.7L; volume of distribution at steady-state, 64.8 +/- 12.5L; total body clearance, 53.8 +/- 1.2 L/h; distribution half-life, 4.1 +/- 1.3 min; and elimination half-life, 70.2 +/- 9.9 min.",Pharmacokinetics and EEG effects of flumazenil in volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044332/),l,16,272930,DB01205,Flumazenil
,2044332,volume of distribution at steady-state,"The pharmacokinetic parameters were (mean +/- SD): initial volume of distribution, 16 +/- 5.7L; volume of distribution at steady-state, 64.8 +/- 12.5L; total body clearance, 53.8 +/- 1.2 L/h; distribution half-life, 4.1 +/- 1.3 min; and elimination half-life, 70.2 +/- 9.9 min.",Pharmacokinetics and EEG effects of flumazenil in volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044332/),l,64.8,272931,DB01205,Flumazenil
,2044332,total body clearance,"The pharmacokinetic parameters were (mean +/- SD): initial volume of distribution, 16 +/- 5.7L; volume of distribution at steady-state, 64.8 +/- 12.5L; total body clearance, 53.8 +/- 1.2 L/h; distribution half-life, 4.1 +/- 1.3 min; and elimination half-life, 70.2 +/- 9.9 min.",Pharmacokinetics and EEG effects of flumazenil in volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044332/),[l] / [h],53.8,272932,DB01205,Flumazenil
,2044332,distribution half-life,"The pharmacokinetic parameters were (mean +/- SD): initial volume of distribution, 16 +/- 5.7L; volume of distribution at steady-state, 64.8 +/- 12.5L; total body clearance, 53.8 +/- 1.2 L/h; distribution half-life, 4.1 +/- 1.3 min; and elimination half-life, 70.2 +/- 9.9 min.",Pharmacokinetics and EEG effects of flumazenil in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044332/),min,4.1,272933,DB01205,Flumazenil
,2044332,elimination half-life,"The pharmacokinetic parameters were (mean +/- SD): initial volume of distribution, 16 +/- 5.7L; volume of distribution at steady-state, 64.8 +/- 12.5L; total body clearance, 53.8 +/- 1.2 L/h; distribution half-life, 4.1 +/- 1.3 min; and elimination half-life, 70.2 +/- 9.9 min.",Pharmacokinetics and EEG effects of flumazenil in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044332/),min,70.2,272934,DB01205,Flumazenil
